Access recently published
whitepapers, podcasts,
DVD’s and more. 

Advisory Board

Dr. Don Jacobs, University of North Carolina Charlotte

Dr. Jon Mason, Heptares Therapeutics Ltd.

Dr. Stephan Schurer, University of Miami

Dr. Xiayang Qiu, Pfizer, Inc.

Dr. David Dalgarno, ARIAD Pharmaceuticals, Inc.

Dr. Gergely Toth, University of Cambridge

Dr. Scot Mente, Pfizer Global R&D Groton Labs

Reasons to Attend:

• HEAR about novel ligand-centric approach for force field calculation.
• BE inspired to set up ambitious projects on SBDD using automated analytics pipeline and long-timescale explicit molecular simulation.
• EXAMINE the role of water/solvent in structure-based drug design.
• RE-DISCOVER the potential of fragment-based drug design through simulation of the complete binding process.
• EXPLORE the epigenomic protein landscapes of cancer cells for drug design.
• MEET potential collaborators from both academic and industry practitioners.

Sessions:

• Structure-Based Drug Design for Kinase
• Drug Resistance
• Force Field Calculation
• GPCR
• Water & Solvation in Drug Design
• Fragment-Based Drug Design
• Protein-Protein Interaction
• Epigenetic Targeting